Association between diabetes mellitus and incidence and case-fatality after stroke due to intracerebral haemorrhage: a retrospective population-based cohort study by Boulanger, Marion et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Association between diabetes mellitus and incidence and case-
fatality after stroke due to intracerebral haemorrhage: a
retrospective population-based cohort study
Citation for published version:
Boulanger, M, Salman, R, Kerssens, J & Wild, S 2017, 'Association between diabetes mellitus and
incidence and case-fatality after stroke due to intracerebral haemorrhage: a retrospective population-based
cohort study', Diabetes Obesity & Metabolism. https://doi.org/10.1111/dom.12934
Digital Object Identifier (DOI):
10.1111/dom.12934
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Diabetes Obesity & Metabolism
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
1 
Title: Association between diabetes mellitus and incidence and case-fatality after stroke due 
to intracerebral haemorrhage: a retrospective population-based cohort study 
DOM-16-0828-OP 
	
Short title: Diabetes mellitus and intracerebral haemorrhage 
Authors 
Marion Boulanger MD,*1,2 Rustam Al-Shahi Salman PhD,1 Jan Kerssens PhD,3 and Sarah H. 
Wild PhD,4 on behalf of the Scottish Diabetes Research Network epidemiology group 
 
Affiliations 
1 Centre for Clinical Brain Sciences, The University of Edinburgh, First Floor, Chancellor’s 
Building, 49 Little France Crescent, Edinburgh. EH16 4SB. UK 
2 Normandie Université, UNICAEN, Inserm U1237, Caen, CHU Côte de Nacre, Service de 
Neurologie, Caen, France 
3 Information Services Division, NHS National Services Scotland, Gyle Square, 1 South Gyle 
Crescent, Edinburgh. EH12 9EB. UK 
4 Usher Institute for Population Health Sciences and Informatics, The University of 
Edinburgh, Medical School, Teviot Place, Edinburgh. EH8 9AG. UK 
 
Corresponding author details (*): 
Dr Marion Boulanger 
Normandie Université, UNICAEN, Inserm U1237 
CHU Côte de Nacre, Service de Neurologie, Caen, France 
Avenue de la Côte de Nacre, 14000 Caen – France 
marion.boulanger@club-internet.fr 
Phone: +33 (2) 31 06 46 17 – fax: +33 (2) 31 06 46 27 
 
 
Abstract word count: 180 
Main text word count: 1800 
2 tables 
Supplementary appendix: supplemental methods, 2 figures, 1 table, supplemental references 
References: 15 
2 
Abstract 
We investigated the associations between types of diabetes and ICH incidence and case-
fatality after ICH, in a retrospective cohort study of people aged 40-89 years in Scotland 
2004-2013 using linkage of population-based records of diagnosed diabetes, hospital 
discharges and deaths. We calculated ICH incidence and 30-day case-fatality after hospital 
admission for ICH and their relative risks (RR) and 95% confidence intervals (95%CI) for 
people with type 1 or type 2 diabetes compared to people without diabetes adjusting for age, 
sex and socio-economic status (SES). There were 77, 1275 and 9778 incident ICH and case-
fatality (95% CI) was 44 (33, 57)%, 38 (35, 41)% and 36% (35, 37)% in people with type 1, 
type 2 and without diabetes, respectively. In comparison to the non-diabetic population, type 
1 diabetes was associated with a higher incidence of ICH (1.74, 95%CI 1.38-2.21) and case 
fatality after ICH (1.35, 95%CI 1.01-1.70), after adjustment for age, sex and SES. Small 
increases in ICH incidence 1.06, 95%CI 0.99-1.12) and case-fatality 1.04, 95%CI 0.96-1.13) 
in people with type 2 diabetes compared to non-diabetic people were not statistically 
significant. 
 
 
Keywords: Case fatality, Epidemiology, Haemorrhagic stroke, Incidence, Intracerebral 
haemorrhage, Risk factors, Type 1 diabetes, Type 2 diabetes 
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Introduction 
Uncertainties remain about the association between diabetes mellitus and the incidence of 
intracerebral haemorrhage (ICH) and case fatality after ICH (1-3). Previous studies have not 
stratified analyses by type of diabetes and variations in individual studies may be partly 
explained by differential effects of type of diabetes on ICH. It is important to understand the 
risk of ICH among people with diabetes to inform decisions about use of anti-thrombotic 
treatment for primary and secondary prevention of other cardiovascular diseases. 
We investigated the associations between diabetes and the incidence and 30-day case-fatality 
after ICH compared to the non-diabetic population separately for type 1 and type 2 diabetes. 
 
Methods 
In a nation-wide population-based retrospective cohort study in 2004-2013, we linked 
population-based data from the national register of diagnosed diabetes (Scottish Care 
Information-Diabetes Collaboration [SCI-DC]; and records of hospital discharges and deaths 
in Scotland. SCI-DC is populated by daily downloads from primary and secondary care and 
is estimated to include >99% of people with diagnosed diabetes in Scotland since 2004 (S1, 
S2, S3). Classification of type of diabetes was based on an algorithm that started with the 
initial record of type of diabetes and re-classification of the diagnosis of type 1 to type 2 
diabetes if either of the following criteria were met: there were recurrent records of 
sulfonylurea prescription or there were no records of insulin prescription. 
We calculated the age-, sex- and socio-economic status (SES)-adjusted relative risk (RRs) 
and 95%CIs for the incidence of ICH (both fatal ICH in the community and ICH resulting in 
hospital admission) and 30-day case-fatality after hospital admission for ICH in people with 
type 1 and type 2 diabetes compared to absence of diabetes. We compared the age-
standardised ICH incidence in this cohort with previous population-based cohort studies 
performed in Britain. As the other studies reported ICH incidence in people of all ages, we 
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calculated ICH incidence in our cohort in people of all ages, combining people with and 
without diabetes.  
Individual-level data on prevalence of hypertension and use of anti-thrombotic drugs – which 
are known risk factors for ICH (2, 4) were not available for the non-diabetic population in 
this study. However, we investigated the potential for confounding by hypertension (using 
anti-hypertensive treatment as a proxy) and anti-thrombotic drug use by using individual 
level data from SCI-DC and aggregated data on age- and sex-stratified national prescribing 
data for the whole population for 2009 (the mid-year of the study period). Further details of 
the methods are provided in file S1 of the supplementary material. We estimated proportions 
of people receiving each drug class by age, sex and diabetes status, and used chi-square tests 
to assess whether proportions of people receiving prescriptions for these drugs differed by 
diabetes status.  
 
Results 
Participants 
After excluding people with missing SES (n=1144) and people with diabetes other than type 
1 or type 2 (n=1389), we included 14,671 people with type 1 diabetes, 189,769 people with 
type 2 diabetes and 2,427,087 people without diabetes (Figure S1). Compared to the 
population without diabetes, there was a larger proportion of men than women among people 
with diabetes (p=0.06 for type 1 and p<0.0001 for type 2 diabetes), people with type 1 
diabetes were younger (p=0.05) and people with type 2 diabetes were older (p<0.001). 
Duration of diabetes was longer and HbA1c was higher in people with type 1 than type 2 
diabetes (Table 1). Proportions of people with systolic blood pressure (BP) recorded 
≤140mmHg were 79% and 74.5%, Body Mass Index (BMI)<25 were 38.1% and 13% and 
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total cholesterol level ≤5mmol/l were 71.5% and 74.1% for type 1 and type 2 diabetes, 
respectively. 
 
ICH incidence  
11,130 people were admitted to hospital for ICH or died from ICH prior to hospital admission 
during 2004-2013: 77 (0.7%) among people with type 1 diabetes, 1275 (11.5%) with type 2 
diabetes, and 9778 (87.8%) without diabetes. After adjustment for age, sex and SES, type 1 
diabetes was associated with a higher ICH incidence (p<0.0001), but there was no evidence 
of an association with type 2 diabetes (p=0.091) compared to the non-diabetic population. 
There was no interaction between diabetes and sex (p=0.89 for type 1 and p=0.77 for type 2 
diabetes) and between diabetes and SES on ICH incidence for either type of diabetes (p=0.20 
for type 1 and p=0.05 for type 2 diabetes; Table 1).  
 
Comparison with previous British population-based cohort studies  
The age-standardised ICH incidence in the total population of Scotland of all ages was 12.9 
per 100,000 person-years (95%CI, 12.2-13.6). Compared to British population-based studies 
of ICH incidence in entire populations, the estimate in this study was similar to those 
identified in studies by Smeeton (S4), Samarasekera (S5), Bamford (S6) and Syme (5) but 
higher than the one found by Rothwell (6) (Figure S2).  
 
ICH case-fatality 
8900 (80%) of the 11,130 people with incident ICH were admitted to hospital. 30-day case-
fatality after hospital admission was higher in people with type 1 diabetes than in people 
without diabetes after adjustment for age, sex and SES (p=0.0424). Case-fatality following 
hospital admission for ICH was similar in people with type 2 diabetes and without diabetes 
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after adjustment for age, sex and SES (p=0.3234). There was no interaction between diabetes 
and sex (p=0.26 for type 1 and p=0.82 for type 2 diabetes) and between diabetes and SES on 
case-fatality for either type of diabetes (p=0.31 for type 1 and p=0.68 for type 2 diabetes; 
Table 2).  
 
Comparison in anti-hypertensive and anti-thrombotic drugs by diabetes status 
People with type 1 and type 2 diabetes were significantly (p<0.0001) more likely to receive 
treatment with anti-hypertensive and anti-thrombotic drugs than people without diabetes in 
all age and sex strata with the exception of people with type 1 diabetes aged 80-89 (table S1). 
 
Discussion  
In this first study investigating the association between diabetes types and ICH, we found that 
people with type 1 diabetes had a higher ICH incidence and 30-day case-fatality after ICH 
after adjustment for age, sex and SES, compared to the non-diabetic population. Small, non 
significant associations were observed between type 2 diabetes and ICH incidence and case-
fatality in similar analyses. We undertook a sensitivity analysis for the subgroup admitted to 
hospital, which did not change the overall associations (age-, sex- and SES-adjusted RR of 
ICH 1.73, 95%CI 1.31-2.23 for type 1 and 1.07, 95%CI 0.99-1.15 for type 2 diabetes among 
people admitted to hospital) suggesting that the inclusion of ICH deaths outside hospital does 
not affect the association with diabetes. 
The shorter duration of diabetes and the better control of glycaemic level and other vascular 
risk factors (such as hypertension) in people with type 2 than type 1 diabetes could partly 
explained the absence of significant association between type 2 diabetes and ICH incidence. 
It is also possible that people with undiagnosed type 2 diabetes were included in the non-
diabetic group because there is no systematic population-screening programme for diabetes in 
Scotland, which could have underestimated the association between type 2 diabetes and ICH. 
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The strengths of the study include the use of a population-based study using data from 
national registers minimising selection bias and providing a large enough sample size to 
investigate the association between type 1 diabetes and ICH, although it is possible that the 
association reflects a chance finding. We were able to adjust associations for the potential 
confounding factors of age, sex, and SES and to investigate potential effect modification of 
diabetes by these factors that has been observed previously (7-9). However, we cannot 
exclude the possibility of residual confounding from risk factors for ICH incidence such as 
hypertension and anti-thrombotic drug use (2, 4). Although individual data on BP and anti-
thrombotic drugs are available within the diabetes register, similar data are not available for 
the non-diabetic population. We are therefore unable to adjust for differences in risk factor 
and treatment patterns between people with and without diabetes. Our findings suggest that 
people with diabetes are more likely to receive treatment with anti-hypertensive and anti-
thrombotic drugs. It is likely that adjustment for exposure to anti-thrombotic drugs would 
reduce the strength of the association between diabetes and ICH incidence. Adjustment for 
hypertension and anti-hypertensive drug on the association between diabetes and ICH 
incidence may also have similar effects although people with diabetes may receive more 
intensive anti-hypertensive treatment than people without diabetes. Uncertainties remain 
about the association between statin use, cholesterol levels, BMI, smoking and incidence of 
ICH (10-12).  
Rothwell’s study, which identified the lowest age-standardised ICH incidence among British 
studies, was conducted in a very wealthy area of Britain, however, our analyses of the 
Scottish population indicated that SES was a minor confounder in the association between 
diabetes and ICH. 
The CALIBER study identified a higher risk of ICH as the first presentation of cardiovascular 
disease among people with type 2 diabetes compared with absence of diabetes based on 84 
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and 2265 ICH respectively after adjustment for several factors including age, sex, 
deprivation, hypertension, cholesterol, statin and anti-hypertensive drugs (hazard ratio=1.28, 
95%CI 1.02-1.62) (13). There were slight differences in age, other characteristics and study 
period between our study and the CALIBER study, which had to exclude 15% of people 
without a code for type of diabetes. The apparent discrepancy between the association 
between type 2 diabetes and ICH in the CALIBER study and ours may reflect chance as the 
CIs for the estimates of RR overlap. Our findings add to those of the CALIBER study by 
describing the association between diabetes and ICH regardless of whether it occurs as the 
first or subsequent cardiovascular event and comparing the effects of type 1 and type 2 
diabetes on both ICH incidence and case-fatality. 
The only study reporting the association between the incidence of haemorrhagic stroke (i.e. 
subarachnoid haemorrhage and ICH combined) and types of diabetes found a similar pattern 
of results to ours, after adjusting for factors including age, hypertension, alcohol intake and 
aspirin use (RR 3.8, 95%CI 1.2-11.8 for type 1 and RR 1.0, 95%CI 0.7-1.4 for type 2 
diabetes) (14). However, this study involved only women and no other studies stratified by 
type of diabetes have been published. The higher risk of ICH in people with diabetes may be 
mediated by the association between diabetes and cerebral small vessel disease (15). The 
higher case-fatality in type 1 diabetes may be explained by the association between 
hyperglycaemia and ICH volume expansion, both of which are independent predictors of 
death after ICH (S7, S8). Further large studies of well-characterised populations are required 
to identify to what extent the associations we found could be explained by confounding and 
to describe the role of diabetes factors such as duration of diabetes and HbA1c as risk factors 
for ICH incidence and case-fatality.  Current approaches to managing cardiovascular risk 
among people with type 2 diabetes in Scotland do not appear to be associated with increased 
risk of ICH incidence or case-fatality.   
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